2 Positive attribute framing increases COVID-19 booster vaccine intention for 3 unfamiliar vaccines. Barnes, K. PhD1, Colagiuri, B. PhD1 4 <sup>1</sup> University of Sydney, Australia 5 6 7 8 9 10 11 12 13 14 15 **Corresponding Author:** 16 Dr. Kirsten Barnes, 17 School of Psychology, A18 University of Sydney 18 19 NSW 2006 20 Australia

21

Email: kirsten.barnes@sydney.edu.au

Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured booster intentions pre- and post-intervention in 1,222 UK-based participants. As hypothesised, vaccine familiarity significantly modulated the effect of framing. While positive framing was effective for the least familiar vaccine (i.e., Moderna), standard negative framing appeared to increase intentions for familiar vaccines

(AstraZeneca/Pfizer), particularly among those with low baseline intentions. These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines – as is currently the case for millions of booster vaccines across the world. Positive framing of

familiar vaccines, however, should be treated with caution.

36 Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) waning over time<sup>1,2</sup> and reduced for emerging variants<sup>3,4</sup>, many countries are accelerating their COVID-19 booster programmes<sup>5,6</sup>. However, vaccine availability does not necessarily translate to vaccine acceptance<sup>7</sup>, with the World Health Organization (WHO) recognising vaccine hesitancy as a global health threat<sup>8</sup>. Side effect apprehension is a primary factor driving hesitancy<sup>9</sup>, with 90% of COVID-19 vaccine refusers fearing side effects more than COVID-19 itself<sup>10</sup>. Further, side effect severity from initial doses has been associated with booster vaccine hesitancy<sup>11</sup>. Reducing perceptions of side effects appears vital for increasing booster acceptance and reducing the global burden COVID-19. The WHO<sup>12</sup> has suggested the framing of vaccine-relevant information<sup>13</sup> could provide a method of reducing negative perceptions. Positive attribute framing, where side effect information is framed in terms of the inverse incidence rate (e.g., "60% will not get a sore arm") as opposed to typical negative framing with the standard incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed consent is maintained due to statistical consistency across frames<sup>14</sup>. Third, there is preliminary evidence that positive attribute framing can improve vaccination attitudes in other settings. For example, one study on the influenza vaccine found positive attribute framing (hereafter positive framing) reduced the expectation and experience of side effects, increased perceived protection from influenza, and reduced distortions in the perception of side effect risk<sup>15</sup>, with results replicated for other vaccine types<sup>16</sup>.

The handful of studies examining framing on COVID-19 vaccine intention have produced mixed results <sup>17-19</sup>. However, those studies focused on vaccine-naïve individuals, did not employ attribute framing, and did not concern booster intentions. Further, those studies also either used fictitious COVID-19 vaccines <sup>17,18</sup> or did not name specific approved COVID-19 vaccines <sup>19</sup>. As such, participants either had limited knowledge of, or investment in, the framed vaccines. As the pandemic has progressed, media discourse <sup>20,21</sup> combined with direct and socially-observed experience of COVID-19 side effects <sup>22</sup>, means it is essential to understand whether positive framing is effective for real-world vaccines where prior knowledge and experience exists. This is particularly important because there is reason to believe that prior knowledge regarding a given COVID-19 vaccine may moderate the strength of any positive framing effect.

Research has shown that greater relevance or belief in a treatment or issue decreases the efficacy of different forms of framing<sup>23,24</sup>, including positive framing on perceptions of hypothetical vaccines<sup>23,25</sup>. The effect of positive framing on vaccine intention may therefore be limited to less familiar vaccines. Even if so, positive framing may still hold utility. New composition changes to COVID-19 booster vaccines have been recommended<sup>26</sup> and are currently being developed<sup>27</sup> to protect against emerging variants. Further, many booster programmes (e.g., in the United Kingdom) require switches from an experienced vaccine (e.g., AstraZeneca Vaxzevria) to a less familiar one (e.g., Moderna Spikevax). Positive framing may therefore be beneficial for increasing uptake for novel vaccines and switches to less familiar vaccines. Yet, because research on positive framing has largely focused on fictitious medications and patient scenarios<sup>23,25,28-32</sup>, the extent to which familiarity moderates the effect of positive framing is currently unclear. Therefore, to understand the extent to which positive framing could be deployed to improve global vaccine uptake to combat

COVID-19, it is critical to test the efficacy of positive framing for genuine familiar and unfamiliar vaccines.


In this pre-registered study (aspredicted.org/53ph4.pdf), positive attribute framing was applied to side effects from genuine manufacturer Patient Information Leaflets (PILs) for the AstraZeneca, Pfizer, and Moderna vaccines and compared to standard negative wording. Participants were randomised to read positive or negatively framed PILs for the same vaccine they had previously received (either AstraZeneca/Pfizer), a familiar vaccine in the UK context (Pfizer/AstraZeneca), or an unfamiliar vaccine (Moderna). It was hypothesised that a) positive framing would increase booster intention, and b) the effect of positive framing would decrease with vaccine familiarity. Following previous research<sup>14,28,33-35</sup> secondary outcome variables concerning booster side effect severity, perceived risk, and booster acceptance, as well as prevalence judgments, were explored as potential mediators of the framing effect on vaccine intention (see Supplementary Materials 1).

100 Results

# Overview

Participants (*N*=1,222) were recruited from the United Kingdom via Pureprofile, an international recruitment service, between 27<sup>th</sup> October and 8<sup>th</sup> November 2021. All were prescreened (see Methods) with data removed on pre-registered quality control criteria (see Supplementary Materials 2). Only those who had received two doses of either the AstraZeneca or Pfizer COVID-19 vaccines were eligible to participate, with participants stratified by their previous vaccine type.

Participants from each stratum were subsequently randomised to one of six experimental conditions (2(Framing)\*3(Familiarity) factorial design; see Figure 1). Baseline ratings were collected regarding primary and secondary outcome measures—all recorded on a 100-point VAS. The primary outcome was the participant's intention to receive a booster vaccine. Secondary outcomes were: 1) perceived booster side effect severity; 2) perceived booster risk; 3) booster acceptance. Wording of items can be found in Figure 1. Familiarity with the side effects of the AstraZeneca, Pfizer, and Moderna vaccines were additionally assessed (100-point VAS) to determine whether side effect knowledge corresponded with the predetermined factorial categories of vaccine Familiarity (i.e., Same > Familiar > Unfamiliar).



120

121

122

Figure 1: Overview of the experimental design, including the item wording for primary and secondary outcomes (Nb. analyses concerning secondary outcomes are contained in Supplementary Materials 1).

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Framed side effect information was subsequently presented dependent on condition using genuine manufacturer PILs for the AstraZeneca, Pfizer, and Moderna vaccines, with side effects presented in standard EU verbal prevalence categories and frequency bands. Positive framing was applied to the frequency bands (for example see Figure 2; full wording and PILs presented as Supplementary Materials 3-4). To manipulate familiarity, participants were randomised to view PILs from the following conditions: 'Same' (PIL for the COVID-19 vaccine previously received: AstraZeneca-AstraZeneca|Pfizer-Pfizer); 'Familiar' (PIL for a common vaccine not previously received: Pfizer-AstraZeneca|AstraZeneca-Pfizer); 'Unfamiliar' (PIL for a less common vaccine in the UK: AstraZeneca-Moderna|Pfizer-Moderna). Familiarity was judged on UK data (22<sup>nd</sup> September 2021), where fewer Modena second doses (1.2 million) had been administered relative to the Pfizer and AstraZenca vaccine (19.4 and 24.0 million respectively)<sup>36</sup>. After timed PIL presentation of 2 minutes, all participants provided post-manipulation ratings for the primary and secondary outcomes (as above). Participants were then presented with 14 side effects from their assigned PIL and were required to: 1) assign each to a verbal prevalence category (i.e., very common, common, uncommon, rare, very rare); 2) estimate frequency of occurrence (number of people in 100,000 expected to experience the side effect (results in Supplementary Materials 1.4.1).

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)	
Common (may affect up to 1 in 10 people)	Common (90 in 100 or more people may <i>not be</i> <i>affected</i> )		Common: 90 in 100 (blue circles) or more not affected
Uncommon (may affect up to 1 in 100 people)	Uncommon (990 in 1,000 or more people may not be affected)		Uncommon: 990 in 1,000 (blue circles) or more not affected

Figure 2: Positive and negative wording used to frame common and uncommon side effects (wording for all prevalence categories can be found in Supplementary Materials 3)

# **Descriptive Statistics**

141

142

143

144

145

146

147

148

149

150

151

152

153

154

#### Sample demographics

Information regarding participant location, age, education, and employment can be found in Figure 2a-b. Participants were 52.5 years of age on average (range=18-95). They resided across most postal areas in the UK, with the largest proportion from London district (N=53), Birmingham (N=35), and Belfast (N=34). Only Harrogate, and the Orkney and Shetland Islands were not represented. The largest proportion of respondents identified as British (N=1,064; 87%), female (N=706; 58%), had completed undergraduate-level education (N=413; 34%), and were in full-time employment (N=407; 33%). Descriptive statistics for the full sample, and by condition, are presented as Supplementary Materials 5-6.

COVID-19 exposure and vaccine history

Most participants (N=1,074; 88%) had not personally been infected with COVID-19,
while 565 (46%) reported infections among family and close friends. On average, participants
had their last COVID-19 vaccine 4.8 months ago. The largest proportion reported not
experiencing side effects to either dose (N=579; 47%). Of those who did, the first dose was most
associated with severe side effects (N=372; 30%).




Figure 3: Demographic Information, where 3a plots the frequency of participants from each postal area of the UK against the vaccination rates reported by the UK government on the 3<sup>rd</sup> November (the final week of data collection) and 3b depicts education and employment categories, and age range, across experimental conditions. *Nb.* 6 participants, 0.5% of the sample, are not represented in 3a due to not providing a valid postal code.

# **Primary Analysis**

Knowledge of vaccine side effects mirrors categorical levels of the Familiarity factor

To determine whether side effect familiarity corresponded with the predetermined factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way ANOVA (with Greenhouse–Geisser correction) was run on side effect familiarity ratings collected for the three vaccine types prior to the experimental manipulation. A robust main effect of Familiarity was observed ( $F(1.86, 2272.18)=659.17, p<.001, \eta_p^2=.35$ ). Awareness of side effects increased with Familiarity; being higher for the Same vs. Familiar vaccine (t(1221)=14.11, p<.001, Cohen's  $d_z=.40$ ), and for the Familiar vs. Unfamiliar vaccine (t(1221)=23.97, p<.001, Cohen's  $d_z=.69$ ). Mean differences are presented in Figure 4e.

#### Baseline vaccine intention

A 2(Framing)\*3(Familiarity) ANOVA was conducted on Baseline Booster Intention scores to assess the presence of between-group differences. Baseline Booster Intention was anticipated to be high across conditions (see pre-registration), which was confirmed in the present sample (M=78.36 (/100-point VAS), SD=31.65; range:0-100). However, an unanticipated significant effect of Familiarity was observed(F(2, 1216)=49.51, p<.0001,  $\eta_p$ <sup>2</sup>=.075). This effect reached significance for the orthogonal contrast comparing the Same vs. Other (i.e., combined Familiar and Unfamiliar) vaccine types (F(1, 1216)=96.51, p<.0001,  $\eta_p$ <sup>2</sup>=.074), but not for the Familiar vs. Unfamiliar comparison (F(1, 1216)=2.42, p=.120,  $\eta_p$ <sup>2</sup>=.002), indicating higher intentions for previously experienced vaccines.

#### Effect of Framing and Familiarity on the intention to be vaccinated

The pre-registered primary analysis plan was a 2(Framing: Positive vs. Negative)\*3

(Familiarity: Same, Familiar, Unfamiliar) factorial ANCOVA, with Baseline Booster Intention for the vaccine presented in the participant's assigned PIL as the covariate, and Post-Manipulation Booster Intention the outcome. However, the fact that Baseline Intention unexpectedly differed systematically with Familiarity meant that including it as a covariate without including its interactions with the manipulated variables (Framing and Familiarity) would violate the assumptions of ANCOVA<sup>37</sup>. To address this, we extended the model to include the interactions between Baseline Booster Intention and Framing and Familiarity in all analyses, as recommended elsewhere<sup>38</sup>. Pre-specified orthogonal contrasts for Familiarity were: Contrast1 (Same vs. Other [Familiar and Unfamiliar combined]); Contrast2 (Familiar vs. Unfamiliar). A Framing\*Familiarity interaction was hypothesised, with the effect of Framing (increased Booster Intention following Positive vs. Negative framing) reducing with increased Familiarity.

Main effects analysis revealed the anticipated Framing\*Familiarity interaction (F(2, 1210)=10.75, p<.0001,  $\eta_p^2=.018$ ). Specifically, Framing interacted with Contrast1 (Same vs. Other: F(1, 1210)=5.07, p=.025,  $\eta_p^2=.004$ ) and Contrast2 (Familiar vs. Unfamiliar: F(1, 1210)=16.46, p=.0001,  $\eta_p^2=.013$ ). As demonstrated in Figure 4a, this pattern of results was driven by Positive Framing increasing Booster Intention for the Unfamiliar vaccine. However, this was superseded by a three-way interaction with Baseline Booster Intention (F(2, 1210)=7.65, p=.0005,  $\eta_p^2=.013$ ), represented at both Contrasts (Baseline\*Framing\*Contrast1: F(1, 1210)=4.39, p=.036,  $\eta_p^2=.004$  | Baseline\*Framing\*Contrast2: F(1, 1210)=11.19, p=.0008,  $\eta_p^2=.009$ ). Figure 4b depicts this interaction. Positive Framing had limited efficacy at high levels of Baseline Intention across Conditions but took effect for the Unfamiliar Vaccine when model

estimated Baseline Intention scores were lower than ~80/100. At very low levels of Baseline Intention (i.e., VAS=0), model predicted Booster Intention Post-Manipulation increased from M=19.09 (SEM=2.76, 95% CIs[13.68, 24.50]) for the Negative Frame, to M=35.11 (SEM=2.77, 95% CIs[29.68, 40.50]) for the Positive Frame. Full model output is included as Supplementary Materials 7. We note that the same interaction between Framing and Familiarity was observed in the planned but invalid model excluding the interaction between these factors and Baseline Booster Intention (see Supplementary Materials 8).

### The effect of Framing on vaccine switches

Analyses were performed to investigate the effect of framing on pre-registered and realistic vaccine switches occurring as part of the UK's booster programme. Specifically, those without medical exemption, who previously received the AstraZeneca vaccine will be required to switch to Pfizer or Moderna, while those who received Pfizer may be required to switch to Moderna.

First, previous vaccine type (AstraZeneca/Pfizer) was entered as a factor in the ANCOVA model above to check for interactions with Framing, Familiarity, and Baseline Booster Intention. While there was a main effect of previous vaccine type (F(1, 1198)=6.36, p=.012,  $\eta_p^2=.005$ ), with those receiving AstraZeneca reporting increased Booster Intention (M=80.83, SEM=0.74, 95% CIs [79.37, 82.29]) compared to Pfizer (M=78.01, SEM=0.74, 95% CIs [76.57, 79.46]), there were no two- or three-way interactions with Framing or Familiarity (all ps>.05; see Supplementary Materials 9).

#### Previous vaccine: AstraZeneca

Representative of a switch from AstraZeneca to Pfizer or Moderna, a 2(Framing)\*2(Familiarity: Familiar (Pfizer), Unfamiliar (Moderna)) ANCOVA (modelling interactions between covariate and factors), was conducted among those who had previously received the AstraZeneca vaccine (N=410). A three-way Framing\*Familiarity\*Baseline Intention interaction was observed ( $F(1, 402)=11.38, p=.0008, \eta_p^2=.028$ ). As demonstrated in Figure 4c, in the case of the Unfamiliar vaccine (Moderna) Booster Intention was increased in the Positive Frame at low levels of Baseline Booster Intention. However, the inverse of this pattern was observed for the Familiar vaccine (Pfizer), where Positive Framing decreased Booster Intention at low levels of Baseline Intention.

### Previous vaccine: Pfizer

Representative of a switch from Pfizer to Moderna, a one-way ANCOVA investigating the effect of framing on the perception of the Unfamiliar (i.e., Moderna) PIL was performed on the data of those who had previously received the Pfizer vaccine (N=202). There was a main effect of Framing (F(1, 198)=3.98, p=.048,  $\eta_p$ <sup>2</sup>=.020), but no statistically significant Baseline Booster Intention\*Framing interaction (F(1, 198)=1.80, p=.181,  $\eta_p$ <sup>2</sup>=.009). However, as demonstrated in Figure 4d, slopes for the Positive and Negative Frame converged at high levels of Baseline Booster Intention.




Figure 4: Model estimated mean differences in the primary outcome (Booster Intention), depicted for the whole sample (4a and 4b), and for realistic switches occurring as part of the UK booster programme (4c and 4d). 4e presents data demonstrating that side effect familiarity ratings scaled with the factorial levels of Vaccine Familiarity. All error bars represent ± 1SEM.

261 Discussion

Message framing has been suggested as a potential intervention to increase COVID-19 vaccine uptake<sup>12</sup>. We examined the effect of positive and negative attribute framing of side effect information on booster intentions for three genuine COVID-19 vaccines varying in familiarity. Positive framing successfully increased booster intention for the unfamiliar vaccine (i.e.,

Moderna), but reduced intention for the vaccine previously received, as well as for a switch to Pfizer among those previously receiving AstraZeneca. In all cases, effects were strongest at low baseline booster intentions. Increasing booster acceptance among those with low intentions is of substantial importance in protecting against infection from, and transmission of, COVID-19 viruses. Critically, our data suggest that any intervention intending to employ attribute framing should be carefully tailored to match the framed information (positive vs. negative wording) with vaccine familiarity. Specifically, positive framing appears to have significant potential in situations where a novel vaccine or composition changes are being introduced<sup>26,27</sup>. By contrast, positive framing may actually be harmful when the vaccine is familiar.

The effect of positive attribute framing on booster intentions for the Unfamiliar vaccine is consistent with medical decision-making research. In these studies, framed information has typically been presented regarding fictitious medications and patient scenarios<sup>23,25,28-32</sup>. When employing real treatments, data has been collected from samples where participants were completely<sup>15,39</sup> or largely<sup>40</sup> naïve to the framed treatment, or where prior treatment experience was not assessed<sup>16,41</sup>. The current data thereby provide new insights into the effect of framing. Under conditions directly relevant to the COVID-19 pandemic (i.e., for real vaccines, at high levels of public involvement), the benefit of positive attribute framing was found to wane, or be reversed, as familiarity and prior experience with the framed vaccine increased. As such, calls for all PILs to employ positive framing as standard (e.g.,<sup>28,42</sup>) appear premature. Instead, negative framing, the standard form for communicating side effect information within the European Union, appears beneficial when treatments are well known.

The reduced efficacy of positive framing with increased vaccine familiarity could be explained by a current theory of attribute framing that posits an interaction between familiarity (a manifestation of psychological distance) and the valence of the message surrounding a given attribute or event (e.g., the experience of vaccine side effects). At closer psychological distances (e.g., for vaccines that are more familiar and more likely to be received), negatively framed information has been shown to be more persuasive<sup>43</sup>. Further experimental research is needed to test this theory, while considering alternative explanations, such as the role of potential backfire effects in persuasive or corrective messaging. Such effects are known to impact attitudes surrounding the COVID-19 pandemic<sup>44</sup> and have been demonstrated to lower intentions for other vaccine types at high levels of concern<sup>45</sup>. However, when assessed in conjunction, current results highlight the fact that any intervention that strives to apply positive framing across all vaccine types, irrespective of familiarity, should be treated with caution.

The psychological mechanisms underlying the effect of positive framing on booster intentions remain unclear. We measured secondary variables as potential mediators. However, results did not mirror those obtained for the primary outcome – booster intention (see Supplementary Materials 1). While changes in secondary variables (side effect severity and booster acceptance) were observed with framing, post-hoc analysis (see Supplementary Materials 10) plotting the Familiarity\*Framing\*Baseline interaction for those who had high vs. low baseline booster intent, suggested that these framing-induced changes largely occurred among those with high vaccine intention at baseline. As these participants also showed limited effect of framing on their behavioural intention to be vaccinated, the relationship between booster intention and our secondary predictors appears orthogonal. Investigation of other factors

combined with qualitative research may be better positioned to identify the driving factors behind the effect of framing on COVID-19 booster intentions. Further, we note that, consistent with previous reports<sup>35,46-49</sup>, prevalence judgements were poor (<~35% accuracy; Supplementary Materials 1.4). This appeared exacerbated among those receiving positive framing, but again did not differ by familiarity. As side effects differed by PIL, the current study was designed only to test for general inaccuracies in side effect representation and not systematic over- or underestimation. Experimental studies are therefore needed to assess precisely how any inaccuracies associated with positively framed COVID-19 vaccine information manifest.

The primary strength of the present study is the application of attribute framing to real COVID-19 vaccine information. The PILs employed here are displayed on government and NHS websites in the UK, forming a primary official source of information regarding COVID-19 vaccination. Our findings therefore have real-world implications, demonstrating that the wording of PILs can directly impact the intention to receive a booster vaccine among individuals for whom this decision is both directly relevant and imminent. There are of course some limitations worth noting including the collection of cross-sectional data that limits an assessment of the durability of the framing effect, as well as a sample located within a single country. Given global differences in booster policy, cross-cultural replication of results is required to ensure results are not contextually limited to the UK. While vaccine intention has been demonstrated to be a strong predictor of vaccine uptake (e.g., 50-52), including for COVID-19 vaccination of sample that the two are synonymous 4. While beyond the scope of the present study, we recommend that future research incorporate longitudinal designs where the rate of conversion from intention to vaccine uptake can be tracked. Further, present results are specific to booster intentions among

those already vaccinated. While side effect apprehension has been associated with hesitancy regarding COVID-19 vaccination<sup>9</sup> and booster vaccination<sup>11</sup>, whether a similar pattern of results would hold among those who have never been vaccinated is unknown.

In summary, the present study demonstrates that the ability of positive framing to successfully increase booster intention for genuine COVID-19 vaccines is critically moderated by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such, we recommend that if positive attribute framing is to be employed, close attention must be paid to the type of treatment being framed as well as the likely recipients of the framed information. Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable of improving uptake of COVID-19 vaccines when switches or new developments require individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes globally.

351 Methods

# **Recruitment and Sample**

Recruitment took place in the initial weeks of the UK booster programme (27<sup>th</sup> October - 8<sup>th</sup> November 2021). Figure 3a provides a summary of the number of boosters administered in the UK at the time of data collection. The sample was obtained from Pureprofile, an ISO-certified panel provider for online research, and balanced on national quotas for age, gender, and region. All potential participants were screened using the following inclusion criteria: 18 years of

age or older, currently residing in the UK, self-reported English fluency, previously received two doses of either the Pfizer or the AstraZeneca COVID-19 vaccines (no other combination), not having received a third COVID-19 booster vaccine, and no known medical reason (e.g., allergy) prohibiting potential administration of the Pfizer, AstraZeneca, or Moderna COVID-19 vaccines. After screening, 1896 participants provided electronic consent and 1459 completed the experiment. To reduce statistical noise due to random and inconsistent responding, 237 completing participants were removed based on pre-registered quality control criteria (see Supplementary Materials 2). The experiment was approved by the University of Sydney Human Research Ethics Committee. All completing participants were provided with an electronic debrief at the end of the survey and were paid £3.50 for a ~15-minute survey.

#### **Data Collection and Procedure**

Cross-sectional data were collected online via Qualtrics, with the survey accessible to personal computer, tablet, and smartphone. The 'force response' option was used to ensure complete cases for all outcome variables. Participants completed the survey in one sitting and were not able to return to the study URL. After pre-screening, those meeting the inclusion criteria were provided with a participant information statement detailing the aims of the study and gave their digital informed consent. Those not meeting these criteria were directed away from the survey.

Participants completed demographic items and identified which COVID-19 vaccine they had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set

to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100 from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas on survey completion but does not account for participants currently in the experimental pipeline, the final sample contained 22 more participants than projected. Statistical analysis did not take place until after exclusions had been made and all quotas were closed.

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

381

382

383

384

385

After randomisation, participants responded to items concerning the number of months since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines. For each vaccine type, participants then rated their booster intention, perceived booster side effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and anxiety). Responses made to the vaccine type that matched with the experimental condition to which the participant had been assigned were employed as baseline measures. Responses to all other vaccine types were recorded for use in a concurrent, but separate, pre-registered study (#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side effect information were then displayed for two minutes, using a timer embedded in the survey. Participants could not proceed until this time had elapsed. Post-manipulation booster intention, perceived booster side effect severity, perceived booster risk, and booster acceptance were then recorded. Finally, fourteen side effects described in the PILs were presented, with participants required to assign each to a verbal prevalence descriptor (very common, common, uncommon, rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would experience the side effect. On completing the survey, all participants were provided with an electronic debrief for download and URLs to the UK government landing page where the original PILs for the vaccines used in the study could be found.

Several additional items concerning general COVID-19 booster intentions, perceived risk of previous COVID-19 vaccines, specific COVD-19 vaccination side effects, general perceptions of COVID-19 and COVID-19 vaccinations, and severity of previous COVID-19 infection, were included in the survey for use in a separate pre-registered study (for information see: #78370; aspredicted.org/8e6af.pdf).

## **Survey Materials**

### Demographic information

Participants responded to items concerning their age, gender, ethnicity, highest level of education and employment status, and geographic region (postal area code). Exact wording can be found in the Demographic Information section, Supplementary Materials 5.

### Previous exposure to COVID-19

Items were employed to capture personal exposure to COVID-19, as well as exposure through close friends and family. Item wording (*To your knowledge, are you, or have you been, infected with COVID-19? / To your knowledge, have any of your close family members or friends been infected with COVID-19?*) was taken from the WHO BeSD documentation<sup>12</sup>.

#### Previous COVID-19 vaccination history

Previous COVID-19 vaccine (Pfizer/AstraZeneca) was recorded as a forced-choice option. Participants indicated the number of months since their last COVID-19 vaccine, and

whether their most severe side effects occurred to their first dose, second dose, whether they were equal across doses, or not experienced at all.

#### Familiarity with COVID-19 vaccine side effects

For the three framed vaccines, participants were asked to rate their "familiarity with the potential side effects" on a 100-point VAS, with anchor labels ('not at all familiar' / 'extremely familiar') positioned to the left and right of the scale. Those who had not heard of the vaccine were asked to check a separate 'not heard of vaccine' box but received a score of zero (not at all familiar). This response-type was used to exclude inconsistent responders (see Supplementary Materials 2).

## Baseline measures: COVID-19 vaccine perceptions

Four items were used as baseline measures. All were rated on a 100-point VAS. For each of the three vaccines, participants responded to questions concerning: 1) booster intention 'If you were offered [vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (labels: 'definitely would not accept vaccine' vs. 'definitely would accept vaccine'); 2) perceived booster side effect severity 'Overall, how severe do you think the [vaccine type] side effects are?' (labels: 'not at all severe' vs. 'extremely severe'); 3) perceived booster risk 'What do you think the risk to your health would be if you received [vaccine type] as a booster vaccine, bearing in mind its side effects?' (labels: 'extremely low risk' vs. 'extremely high risk'); 4) booster switch perceptions 'Imagine that switching to the [vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (labels: 'not at all' vs.

'extremely'). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score of 0-100. Where the vaccine type was the same as that previously received by the participant, wording was changed from 'switching to' to 'continuing with'. Wording of 1-3 was adapted from previous research<sup>35</sup>.

### Patient Information Leaflets (PILs): Experimental manipulation

Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include the manufacturer's description of each vaccine, what it is used for, and critically, the possible side effects resulting from administration. Side effects were retained in their original form and order. For both the negatively and positively framed PILs, verbal descriptors were in keeping with those published by the manufacturer (i.e., very common, common, uncommon, rare, very rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs was also identical to that of the manufacturer. However, this was inverted in the positively framed PILs to stress the number of individuals *not* affected (e.g., "Common (90 in 100 or more people may *not be affected*)"). As multi-modal forms of side effect presentation (e.g., written, pictorial, verbal) may elicit larger framing effects<sup>14</sup>, and numeracy is less likely to moderate the effect of attribute framing for graphical presentations<sup>55</sup>, positive PILs additionally included a graphical representation of side effect risk to enhance the manipulation. For an example of the wording used to frame side effects see Figure 2.

#### Post-manipulation measures: COVID-19 vaccine perceptions

Participants responded to the four vaccine perception items listed above under Baseline Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but only in relation to the vaccine type outlined in the PIL to which they were assigned.

#### Post-manipulation side effect perceptions

To determine whether positive framing augments the perception of side effect occurrence relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of these were associated with concrete prevalence brackets in the original PILs, while the remaining three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL publication). For each side effect, participants were required to identify the correct verbal descriptor (very common, common, uncommon, rare, very rare): "based on the information that you read, how common do you think [side effect] is?" (forced-choice answer). They were then asked, "In 100,000 people, how many do you think would experience [side effect] if they received a [framed vaccine name] booster vaccine?" (free-response, limited to numbers at up to 10 decimal places). The three 'unknown' side effects were analysed separately to determine the effect of framing when prevalence rates are not provided.

# **Statistical Analysis**

Statistical analysis was performed using R (version 4.1.1). Statistical analyses were a combination of ANCOVAs (where baseline measures were available) or ANOVAs, reported with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical significance. Sample size (estimated N=1200) was calculated based on an *a priori* power analysis (95% power, alpha=.05, effect size  $f^2=0.02$ ) for a separate study run concurrently that contained

more predictor variables (N=9), and therefore required more power, than the study presented here (further details contained in the study pre-registration form). An effect size for attribute framing was additionally derived from previous research (average effect size r=0.175)<sup>14</sup>. An *a priori* power analysis based on this effect size required a total of 491 participants, providing reassurance that the projected sample size for the study above provided ample power to detect an effect of framing in the present study.

### Acknowledgements

**Sources of Funding**: This research was supported by Australian Research Council grants DP180102061 and DP200101748. The funding body had no involvement in study design, analysis, interpretation, writing, or the decision to submit the present article for publication.

**Data Availability:** The code and raw data necessary to replicate the reported analysis is available through the Open Science Framework repository (means/SEMs needed to reproduce the analysis figures are included with the raw data):

https://osf.io/d5cvn/?view\_only=500c83d90bb9416796e464108ad2fc41

**Author contributions:** KB and BC conceived the experimental design. KB was responsible for collecting and analysing the data. KB wrote the first draft of the article. BC edited and contributed to the final version.

# References


516 1 Andrews, N. et al. Vaccine effectiveness and duration of protection of Comirnaty, 517 Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint at: 518 https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 (2021). 519 2 Goldberg, Y. et al. Waning immunity of the BNT162b2 vaccine: A nationwide study 520 from Israel. Preprint at: https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1(2021). 521 522 3 Cele, S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer 523 BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at: 524 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855.2/ (2021). Basile, K. et al. Improved neutralization of the SARS-CoV-2 Omicron variant after 525 4 526 Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. Preprint at: 527 https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1.abstract (2021). 528 5 Mahase, E. Covid-19 booster vaccines: What we know and who's doing what. BMJ 374, n2082 (2021). 529 530 6 All adults to be offered COVID-19 boosters by end of January (gov.uk, 2021); 531 https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-532 of-january 533 7 MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 33, 534 4161-4164 (2015). 535 8 Ten threats to global health in 2019 (World Health Organisation, 2019); 536 https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 537 9 Solís Arce, J. S. et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-538 income countries. Nature Medicine 27, 1385-1394 (2021). 539 10 Why won't Americans get vaccinated? (Economist/YouGov poll, 2021); 540 https://today.yougov.com/topics/politics/articles-reports/2021/07/15/why-wont-541 americans-get-vaccinated-poll-data 542 11 Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19 543 Vaccine Dose in Poland. Vaccines 9, 1286 (2021). 544 12 World Health Organization. Data for action: achieving high uptake of COVID-19 545 vaccines: gathering and using data on the behavioural and social drivers of vaccination: 546 a guidebook for immunization programmes and implementing partners: interim

- 547 *guidance, 1 April 2021.* (World Health Organization, 2021);
- 548 <a href="https://apps.who.int/iris/handle/10665/340645">https://apps.who.int/iris/handle/10665/340645</a>
- Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A
- Typology and Critical Analysis of Framing Effects. Organizational Behavior and Human
- 551 Decision Processes **76**, 149-188 (1998).
- 552 14 Barnes, K. et al. Can Positive Framing Reduce Nocebo Side Effects? Current Evidence
- and Recommendation for Future Research. Frontiers in Pharmacology 10, 167 (2019).
- 554 15 O'Connor, A. M., Pennie, R. A. & Dales, R. E. Framing effects on expectations,
- decisions, and side effects experienced: The case of influenza immunization. *Journal of*
- 556 *Clinical Epidemiology* **49**, 1271-1276 (1996).
- Bigman, C. A., Cappella, J. N. & Hornik, R. C. Effective or ineffective: Attribute framing
- and the human papillomavirus (HPV) vaccine. Patient Education and Counseling 81,
- 559 S70-S76 (2010).
- 560 17 Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A.
- Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the
- United States and the United Kingdom: A Randomized Controlled Trial. Preprint at:
- 563 https://www.medrxiv.org/content/10.1101/2021.10.12.21264877v2 (2021).
- Chen, T., Dai, M., Xia, S. & Zhou, Y. Do Messages Matter? Investigating the Combined
- Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19
- Vaccination Attitudes and Intention. *Health Communication*, 1-8 (2021).
- Huang, Y. & Liu, W. Promoting COVID-19 Vaccination: The Interplay of Message
- Framing, Psychological Uncertainty, and Public Agency as a Message Source. *Science*
- 569 *Communication* **44**, 3-29 (2021).
- Lentzen, M.-P. et al. A retrospective analysis of social media posts pertaining to COVID-
- 571 19 vaccination side effects. *Vaccine* **40**, 43-51 (2022).
- Jamison, A. M. et al. Vaccine-related advertising in the Facebook Ad Archive. Vaccine
- **38**, 512-520 (2020).
- Ndwandwe, D. & Wiysonge, C. S. COVID-19 vaccines. Current Opinion in Immunology
- **71**, 111-116 (2021).

576 23 Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant 577 Immunization: The Influence of Involvement. Health Education & Behavior 27, 82-95 578 (2000).579 24 Benjamin, D., Por, H.-H. & Budescu, D. Climate Change Versus Global Warming: Who 580 Is Susceptible to the Framing of Climate Change? Environment and Behavior 49, 745-581 770 (2016). 582 25 Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within 583 messages to change vaccination behavior. Journal of Communication in Healthcare 8, 584 45-54 (2015). 585 26 Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron 586 SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine 587 Composition (TAG-CO-VAC) (World Health Organization, 2022); 588 https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-inthe-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-589 590 advisory-group-on-covid-19-vaccine-composition 591 27 Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by 592 spring (The Washington Post, 2022); 593 https://www.washingtonpost.com/business/2022/01/11/pfizer-omicron-specific-vaccine/ 594 28 Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two 595 Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A 596 Randomised Trial of 16- to 75-Year-Olds in England. Drug Safety 43, 1011-1022 (2020). 597 29 Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in 598 Health Decisions. Organizational Behavior and Human Decision Processes 85, 382-399 599 (2001).600 30 Levin, I. P., Schnittjer, S. K. & Thee, S. L. Information framing effects in social and 601 personal decisions. Journal of Experimental Social Psychology 24, 520-529 (1988). 602 31 Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of 603 recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in 604 hypothetical patient scenarios. Breast Cancer Research and Treatment 60, 9-14 (2000). 605 32 Marteau, T. M. Framing of information: Its influence upon decisions of doctors and 606 patients. British Journal of Social Psychology 28, 89-94 (1989).

- Webster, R. K. & Rubin, G. J. Predicting Expectations of Side-Effects for Those Which
- Are Warned Versus Not Warned About in Patient Information Leaflets. *Ann Behav Med*
- **12**, 1253–1261 (2021).
- Herber, O. R., Gies, V., Schwappach, D., Thürmann, P. & Wilm, S. Patient information
- leaflets: informing or frightening? A focus group study exploring patients' emotional
- reactions and subsequent behavior towards package leaflets of commonly prescribed
- medications in family practices. *BMC Family Practice* **15**, 163 (2014).
- Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:
- An empirical evaluation of EU recommended terminology. Psychology, Health &
- 616 *Medicine* **8**, 251-263 (2003).
- 617 36 Research and analysis: Coronavirus vaccine weekly summary of Yellow Card reporting
- 618 (gov.uk, 2021); <a href="https://www.gov.uk/government/publications/coronavirus-covid-19-">https://www.gov.uk/government/publications/coronavirus-covid-19-</a>
- vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
- 620 37 Myers, J. L. & Well, A. D. Research design and statistical analysis, 2nd ed. (Lawrence
- Erlbaum Associates Publishers, 2003).
- 622 38 Cardinal, R. N. & Aitken, M. R. F. ANOVA for the behavioural sciences researcher.
- 623 (Lawrence Erlbaum Associates Publishers, 2006).
- Llewellyn-Thomas, H. A., McGreal, M. J. & Thiel, E. C. Cancer Patients' Decision
- Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-
- term Toxicity and Long-term Survival. *Medical Decision Making* **15**, 4-12 (1995).
- Ferguson, E. & Gallagher, L. Message framing with respect to decisions about
- vaccination: The roles of frame valence, frame method and perceived risk. *British*
- 629 *Journal of Psychology* **98**, 667-680 (2007).
- 41 Jasper, J. D., Goel, R., Einarson, A., Gallo, M. & Koren, G. Effects of framing on
- teratogenic risk perception in pregnant women. *The Lancet* **358**, 1237-1238 (2001).
- Webster, R. K., Weinman, J. & Rubin, G. J. Explaining all without causing unnecessary
- harm: Is there scope for positively framing medical risk information? *Patient Education*
- 634 and Counseling **102**, 602-603 (2019).
- Freling, T. H., Vincent, L. H. & Henard, D. H. When not to accentuate the positive: Re-
- examining valence effects in attribute framing. Organizational Behavior and Human
- 637 Decision Processes **124**, 95-109 (2014).

- Dan, V. & Dixon, G. N. Fighting the Infodemic on Two Fronts: Reducing False Beliefs
- Without Increasing Polarization. *Science Communication* **43**, 674-682 (2021).
- Nyhan, B. & Reifler, J. Does correcting myths about the flu vaccine work? An
- experimental evaluation of the effects of corrective information. *Vaccine* **33**, 459-464
- 642 (2015).
- 643 46 Webster, R. K., Weinman, J. & Rubin, G. J. People's Understanding of Verbal Risk
- Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to
- 645 65-Year-Olds in England. *Drug Safety* **40**, 743-754 (2017).
- Berry, D. C., Knapp, P. R. & Raynor, T. Is 15 per cent very common? Informing people
- about the risks of medication side effects. *International Journal of Pharmacy Practice*
- **10**, 145-151 (2002).
- 649 48 Berry, D. C., Raynor, D. K., Knapp, P. & Bersellini, E. Patients' Understanding of Risk
- Associated with Medication Use. *Drug Safety* **26**, 1-11 (2003).
- Knapp, P. et al. Communicating the Risk of Side Effects to Patients. Drug Safety 32, 837-
- 652 849 (2009).
- 653 50 Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in
- Young Adult Women: Comparing the Health Belief Model and Theory of Planned
- Behavior. Annals of Behavioral Medicine 44, 171-180 (2012).
- Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get
- vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel.
- 658 *Vaccine* **32**, 6986-6991 (2014).
- 52 Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:
- Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual
- Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).
- 53 Jensen, U., Ayers, S. & Koskan, A. Video-based messages to reduce COVID-19 vaccine
- hesitancy and nudge uptake. Preprint at: https://psyarxiv.com/df9qw/ (2021).
- Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.
- European Review of Social Psychology 12, 1-36 (2002).
- Kreiner, H. & Gamliel, E. Are highly numerate individuals invulnerable to attribute
- framing bias? Comparing numerically and graphically represented attribute framing.
- European Journal of Social Psychology 47, 775-782 (2017).



# **Baseline Primary Outcome:**

# **Baseline Booster Intention**

'If you were offered [framed vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (100-point VAS)

# **Baseline Secondary Outcomes:**

# Baseline Perceived Booster Side effect Severity

'Overall, how severe do you think the [framed vaccine type] side effects are?' (100-point VAS)

# Baseline Perceived Booster Risk

'What do you think the risk to your health would be if you received [framed vaccine type] as a booster vaccine, bearing in mind its side effects?' (100-point VAS)

# Baseline Booster Acceptance

'Imagine that switching to the [framed vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (100-point VAS)

# Manipulation: Timed presentation of framed PIL information

# **Post-Manipulation Primary Outcome:**

**Booster Intention** 

# Post-Manipulation Secondary Outcomes:

Perceived Booster Side effect Severity
Perceived Booster Risk
Booster Acceptance

# Post-Manipulation Judgement of Side Effect Prevalence

Assignment of PIL side effects to verbal risk brackets

Forced choice assignment to very common, common, uncommon, rare and very rare categories

Estimation of prevalence (X in every 100,000 individuals)

Estimation of how many people in every 100,000 affected

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	Common (90 in 100 or more people may <i>not be affected</i> )	Common: 90 in 100 (blue circles) or more not affected
Uncommon (may affect up to 1 in 100 people)	Uncommon (990 in 1,000 or more people may <i>not be affected</i> )	Uncommon: 990 in 1,000 (blue circles) or more not affected

#### 3a. Frequency of Participants by Location 3b. Demographic Information by Condition **Education by Condition** Other Post-Graduate Undergraduate A-Level **Scotland** NVQ1/NVQ2 1st dose 79.1% GCSE Primary/Secondary 2<sup>nd</sup> dose 71.6% 3<sup>rd</sup> dose 15.7% **Employment by Condition** Unemployed (looking) Unemployed (not looking) Student **Northern** Self-employed Retired Ireland Other Parenting/caring 1<sup>st</sup> dose 70.3% Part-time Full-time 2<sup>nd</sup> dose 65.8% 3rd dose 6.2% Negative Same Negative Familiar Negative Unfamiliar Positive Same Positive Familiar Positive Unfamiliar **England** 1st dose 74.3% 2<sup>nd</sup> dose 67.8% 3<sup>rd</sup> dose 13.3% **Age by Condition** Wales 1<sup>st</sup> dose 77.2% 2<sup>nd</sup> dose 70.9% Negative Unfamiliar 3<sup>rd</sup> dose 15.8% Negative Familiar Negative Same Positive Unfamiliar Positive Familiar Positive Same 100 25 50 **7**5 Participant Frequency Participant Age

30

10

20

50

75 100

